Literature DB >> 17045798

Rapid non-genomic vasoconstrictor actions of aldosterone in the renal microcirculation.

Shuji Arima1.   

Abstract

There is increasing evidence for the pathophysiological importance of aldosterone in renal diseases. Studies have so far demonstrated that aldosterone exerts deleterious renal effects by inducing oxidative stress, endothelial dysfunction, inflammation and fibrosis through a mineralocorticoid receptor (MR)-dependent genomic mechanisms. On the other hand, a number of recent studies provided evidence that aldosterone can act through a rapid non-genomic mechanism in cardiovascular tissues including the kidney, though the relative importance of such actions in renal diseases remains to be determined. We have recently found that physiological concentrations of aldosterone cause rapid vasoconstriction in the renal microcirculation. The vasoconstrictor actions were compatible with non-genomic; the major characteristics was its relatively early onset (apparent within 5min), which was not affected by either actinomycin D or cycloheximide (inhibitors of transcription or protein synthesis). Thus, in addition to genomic actions, such non-genomic vasoconstrictor actions in the renal microcirculation may contribute to the deleterious renal effects of aldosterone in renal diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17045798     DOI: 10.1016/j.jsbmb.2006.09.018

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  2 in total

1.  Aldosterone sensitizes connecting tubule glomerular feedback via the aldosterone receptor GPR30.

Authors:  YiLin Ren; Martin A D'Ambrosio; Jeffrey L Garvin; Pablo Leung; Kristopher Kutskill; Hong Wang; Edward L Peterson; Oscar A Carretero
Journal:  Am J Physiol Renal Physiol       Date:  2014-06-25

2.  Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study.

Authors:  Lene Boesby; Thomas Elung-Jensen; Tobias Wirenfeldt Klausen; Svend Strandgaard; Anne-Lise Kamper
Journal:  PLoS One       Date:  2011-11-04       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.